Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented results of a post-hoc exploratory analysis of the GRIPHON study in patients with pulmonary arterial hypertension (PAH) showing that treatment with UPTRAVI® versus placebo improved clinical outcomes regardless of the time from diagnosis to UPTRAVI initiation, and that the treatment effect was more pronounced in those receiving UPTRAVI soon after diagnosis. The data were presented at the annual American Thoracic Society International Conference in Dallas, Texas.
“This new analysis reinforces the overall efficacy data for selexipag and provides compelling evidence of the benefits of initiating selexipag early,”
said Prof. Sean Gaine, MD, Consultant Respiratory Physician and Director of National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
“These data add to the growing evidence supporting early intensification of treatment, which is important when you consider that around a third of PAH patients currently die within five years of diagnosis. Early recognition and prompt treatment of the disease are key to achieving sustained long-term benefits.”
The GRIPHON study evaluated the long-term efficacy and safety of oral UPTRAVI in 1,156 patients with PAH across 181 centers from 39 countries. It is the largest randomized, controlled, outcome trial ever conducted in patients with PAH, and demonstrated a 40% reduction in the primary composite endpoint of morbidity/mortality, defined as disease progression, worsening of PAH resulting in hospitalization, initiation of intravenous [IV] prostanoid therapy or long-term oxygen therapy, or the need for lung transplantation or balloon atrial septostomy, or death from any cause. Overall, the most common adverse events for patients receiving UPTRAVI were headache, diarrhea, nausea, and jaw pain.
“The GRIPHON study firmly established the importance of the prostacyclin pathway in PAH treatment which will, hopefully, benefit patients worldwide,”
said Richard Channick, MD, Professor of Medicine and Director, Acute and Chronic Thromboembolic Disease Program at UCLA Medical Center.
“This new analysis clearly demonstrates that early treatment is critical if we are to significantly improve long-term outcomes in this serious, progressive disease.”
This post-hoc analysis evaluated the impact of time from diagnosis to initiation of UPTRAVI on the treatment response with respect to the primary endpoint of the study. Patients were categorized at baseline based on their time from diagnosis using a six-month threshold. Patients treated earlier were defined as those who received treatment ≤6 months from diagnosis (N=404), and those who were treated later received treatment >6 months from diagnosis (N=752). UPTRAVI reduced the risk of morbidity/mortality, compared with placebo, in both groups with a risk reduction of 55% for those treated earlier (HR 0.45 [95% CI: 0.33–0.63]) and a risk reduction of 30% for those treated later (HR 0.70 [95% CI: 0.54–0.91]). The response was more pronounced in those treated earlier. This pattern was observed in all background PAH therapy subgroups.
The results of the analysis are consistent with other studies and clinical guidelines that support the early initiation of treatment for PAH.
“This post-hoc analysis of the GRIPHON study adds to the growing body of research which indicates that selexipag can have a significant impact on a patients’ morbidity and disease progression, irrespective of background therapy,”
said Alessandro Maresta, MD, VP and Head of Medical Affairs at Actelion Pharmaceuticals Ltd.
“At Actelion, we have helped impact the lives of more than 300,000 patients with PAH globally over the past 20 years. Today it is essential that current treatments are used to their fullest potential so that we slow disease progression and significantly improve outcomes.”
UPTRAVI is an oral selective prostacyclin IP receptor agonist, and is available for the treatment of PAH in more than 40 countries. In the US, UPTRAVI is indicated for the treatment of PAH to delay disease progression and reduce the risk of hospitalization. In Europe, UPTRAVI is indicated for the long-term treatment of PAH in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.